Abbott Laboratories

Abbott Laboratories (ABT), (Gründungsname: Abbott Alkaloid Company) ist ein weltweit operierender, als Standardwert geltender und im S&P 100 als auch im Dow Jones Global Titans 50 gelisteter Pharmakonzernmit rund 73.000 Mitarbeitern in 150 Ländern.[2] Das Unternehmen wurde 1888 von Wallace C. Abbott (1857–1921) gegründet und hat seinen Hauptsitz in Abbott Park, einem nördlichen Vorort von Chicago, Illinois.
Das Kerngeschäft von Abbott Laboratories liegt in der Erforschung, Entwicklung und Herstellung verschiedener Pharmazeutika aus Humanmedizin und Veterinärmedizin, sowie in den Bereichen Labordiagnostik und klinische Ernährung.
Abbott wurde am 1. Januar 2013 in die zwei unabhängige Unternehmen Abbott und AbbVie aufgeteilt. Abbott ist weiterhin tätig in Bereichen wie Diagnostik, Medizintechnik, Ernährung und etablierten Markenmedikamenten. AbbVie ist ein neu gegründetes forschendes, unter dem Symbol „ABBV“ an der New Yorker Börse gehandeltes BioPharma-Unternehmen mit dem seinerzeit von Abbott Laboratories vermarkteten Portfolio an Spezialmedikamenten. Tätig ist AbbVie unter anderem in den Bereichen Immunologie, Onkologie und Virologie.[3][4][5]
In den Forbes Global 2000 der weltweit größten börsennotierten Unternehmen belegt Abbott Laboratories Platz 421 (Stand: Geschäftsjahr 2017). Das Unternehmen kam Mitte 2018 auf einen Börsenwert von ca. 107 Mrd. US$.[6]

https://de.wikipedia.org/wiki/Abbott_Laboratories

Abbott Laboratories Reports Healthy First-Quarter Profit

Abbott reports earnings above its own guidance and that of Wall Street analysts.

...

Abbott reported adjusted earnings of 63 cents per share on revenue of $7.5 billion, a 2% year-over-year increase. 

Analysts polled by FactSet were expecting the company to report earnings of 61 cents per share on revenue of $7.48 billion. 

...

https://www.thestreet.com/investing/earn...yptr=yahoo

Abbott Laboratories beats by $0.01, beats on revenue


Abbott Laboratories (NYSE:ABT): Q1 Non-GAAP EPS of $0.63 beats by $0.01; GAAP EPS of $0.38.

Revenue of $7.54B (+2.0% Y/Y) beats by $50M.


Nach dem Dip in den vergangenen Tagen (Danke Bernie Sanders! ) gehts heute mal wieder aufwärts...

Abbott (ABT) Q2 Earnings Surpass Estimates

Abbott (ABT) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 2.50%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.61 per share when it actually produced earnings of $0.63, delivering a surprise of 3.28%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.98 billion for the quarter ended June 2019, missing the Zacks Consensus Estimate by 0.10%. This compares to year-ago revenues of $7.77 billion.


...

https://finance.yahoo.com/news/abbott-ab...12766.html

Abbott (ABT) Meets Q3 Earnings Estimates

Abbott (ABT) came out with quarterly earnings of $0.84 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.80 per share when it actually produced earnings of $0.82, delivering a surprise of 2.50%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $8.08 billion for the quarter ended September 2019, missing the Zacks Consensus Estimate by 0.23%. This compares to year-ago revenues of $7.66 billion.


...

https://finance.yahoo.com/news/abbott-ab...12523.html

Abbott (ABT) Meets Q4 Earnings Estimates

Abbott (ABT) came out with quarterly earnings of $0.95 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.81 per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.84 per share when it actually produced earnings of $0.84, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $8.31 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.63%. This compares to year-ago revenues of $7.77 billion.


...

https://finance.yahoo.com/news/abbott-ab...01806.html

Abbott (ABT) Beats Q1 Earnings and Revenue Estimates

Abbott (ABT) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 18.18%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.95 per share when it actually produced earnings of $0.95, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.73 billion for the quarter ended March 2020, surpassing the Zacks Consensus Estimate by 8.38%. This compares to year-ago revenues of $7.54 billion.


...

https://finance.yahoo.com/news/abbott-ab...12113.html

Abbott (ABT) Q2 Earnings and Revenues Beat Estimates

Abbott (ABT) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.82 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 32.56%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.55 per share when it actually produced earnings of $0.65, delivering a surprise of 18.18%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.33 billion for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 7.23%. This compares to year-ago revenues of $7.98 billion.


...

https://finance.yahoo.com/news/abbott-ab...12923.html

Abbott Surges on a Rapid Test Set for U.S. Rollout: Virus Update

(Bloomberg) -- Abbott Laboratories surged after its 15-minute test won emergency clearance in the U.S. The government will buy 150 million of the tests for $750 million under a plan to be announced by President Donald Trump, according to people familiar with the matter.

...

https://finance.yahoo.com/news/record-sp...51707.html

Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates

Abbott (ABT) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.90 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 8.89%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.43 per share when it actually produced earnings of $0.57, delivering a surprise of 32.56%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $8.85 billion for the quarter ended September 2020, surpassing the Zacks Consensus Estimate by 4.67%. This compares to year-ago revenues of $8.08 billion.


...

https://finance.yahoo.com/news/abbott-ab...12874.html